Outlook Therapeutics Inc (OTLK): Patience is my speciality LUNR is leavi...

Next 10 Prev Next

Send PM Follow Ignore

Followers	444
Posts	27789
Boards Moderated	8
Alias Born	09/26/2009

ErnieBilco

Re: Stumblebum post# 1478

Tuesday, 05/26/2026 9:37:49 AM

Tuesday, May 26, 2026 9:37:49 AM

Patience is my speciality LUNR is leaving orbit had it since 2023

Hoping 2026 develops half as well as this lil chickidee

VA VA VA VOOMMMMMM!!!!

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent OTLK News

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 06/02/2026 01:31:05 AM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/02/2026 01:30:12 AM
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/01/2026 09:00:43 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/01/2026 09:00:21 PM
Form 8-K - Current report • Edgar (US Regulatory) • 06/01/2026 01:15:32 PM
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) • GlobeNewswire Inc. • 06/01/2026 12:46:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2026 08:30:49 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/29/2026 12:30:23 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2026 09:09:53 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/27/2026 07:29:11 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/27/2026 07:24:20 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/26/2026 11:15:41 AM
Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg) • GlobeNewswire Inc. • 05/26/2026 11:00:00 AM
Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2026 09:03:14 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:31:12 PM
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/15/2026 08:05:00 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/13/2026 09:12:56 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 08:36:26 PM
Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 05/07/2026 08:24:31 PM
Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2026 08:30:39 PM
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering • GlobeNewswire Inc. • 04/23/2026 08:05:00 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/23/2026 11:30:17 AM
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 08:15:44 PM
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) • GlobeNewswire Inc. • 04/21/2026 01:05:00 PM

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Detailed Quote

Recent OTLK News

More OTLK News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent OTLK News

Go Ad-Free